CEVEC Pharmaceuticals (Germany) a biopharmaceutical company focused on developing and producing therapeutic proteins and monoclonal antibodies with human glycosylation patterns, closed a $5.4M Series B financing. Participants include Creathor Venture, NRW Bank, Sparkasse KolnBonn and ERP Startfonds.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb